Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Table 2 Procedural details in Group I, II and III patients were as follows

Parameter	Group I	Group II	Group III
Volume of marrow aspirated (mL)	149 ± 60	222 ± 22.97	199 ± 49.91
Aspiration - Unilateral/Bilateral	U/L-3, B/L-4	B/L-7	U/L-4, B/L-3
Bone marrow TNC count	11.72 ± 6.36 × 108	20.28 ± 8.55 × 108	11.72 ± 3.03 × 108
Bone marrow MNC count	4.9 ± 3.10 × 108	12.04 ± 4.84 × 108	6.88 ± 2.30 × 108
Bone marrow CD 34+ cell count	0.71% ± 0.45%	0.87% ± 0.35%	0.58% ± 0.30%
Procedure time (min)	57 ± 18	50 ± 8	38 ± 18
Artery cannulated	SPD-5, SMA-2	Splenic-7	IV route
Catheter change required	1 case- multiple times	Nil	NA
SUV max at Pancreas at 30 min (mean ± SD)	21 ± 38	3.4 ± 3.34	1.56 ± 0.34

NA: Not applicable.